The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

June is Myasthenia Gravis Awareness month. We are trying to raise awareness through various activities. One such activity is ...

Despite acknowledging that efgartigimod (Vyvgart), can 'improve symptoms and people’s ability to carry out their normal ...

"Psychological assessments are essential in the management of myasthenia gravis, as the condition is frequently associated ...

Early diagnosis and treatment of generalized myasthenia gravis (MG) are important to achieve symptomatic control and limit ...

ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) ...

Real estate agent Kirsten Jordan breaks down the latest trends in the housing market, near-record home sale cancellations in April and her outlook on mortgage rates. Myasthenia gravis is a rare, ...

Myasthenia Gravis Foundation of America (MGFA™), the largest, leading patient advocacy organization in the United States ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

As such, UCB’s recently-debuted, U.S.-based DTC rare-disease campaign Imagine Your Zillions supports its gMG treatment Zilbrysq. The effort is based on flipping the preconceived notions associated ...

RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Products Administration (NMPA) for the treatment of ...

New research reveals light sensitivity significantly impacts quality of life in myasthenia gravis patients, highlighting the ...